Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Article content
SAN DIEGO and TORONTO, May 14, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) has been selected for oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy.
Article content
The TUS+VEN+AZA triplet is being developed as the only safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. As reported prior, the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet, have demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up.
Article content
Details of the presentation are as follows:
Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy
Session: Oral Presentations: Acute Myeloid Leukemia – Clinical
Session Date and Time: Thursday, June 12, 2025, 5:00 – 6:15 pm CEST
Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine
Abstract #: S139
Article content
Article content
The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes.
Article content
The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
32 minutes ago
- Toronto Star
American Tungsten Advances Zero Level Rehabilitation at IMA Mine
Vancouver, BC, Aug. 20, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) ('American Tungsten' or the 'Company') American Tungsten is pleased to report significant progress in the ongoing rehabilitation of the Zero Level portal at its IMA Mine site, as part of its commitment to safety, operational excellence, and regulatory compliance. Weekly Progress Highlights (Week Ending August 16, 2025):
Toronto Star
32 minutes ago
- Toronto Star
Bitget Boosts Trust with Chainlink Proof of Reserve
VICTORIA, Seychelles, Aug. 20, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced the adoption of Chainlink Proof of Reserve on Ethereum to provide real-time transparency for its wrapped Bitcoin asset, BGBTC. This collaboration also supports the growing use of BGBTC within BitVault Finance's DeFi yield strategies and lending products, enabling both retail and institutional participants to engage with the asset knowing its backing is continuously monitored and verifiable. As blockchain technology reshapes how trust is established in financial markets, Bitget and Chainlink are working together to ensure that proof is not just promised, but provable. 'Transparency is essential in the digital asset industry,' said Gracy Chen, CEO of Bitget. 'By adopting Chainlink's industry-leading Proof of Reserve, we're giving our users and institutional partners the assurance they deserve, knowing that BGBTC is always verifiably backed. This is another step in our mission to deliver secure, transparent, and innovative products for the Web3 space.' ARTICLE CONTINUES BELOW Chainlink Proof of Reserve leverages decentralized oracle networks to autonomously verify the reserve balances backing tokenized assets. By publishing onchain data that reflects real-world asset reserves, Chainlink ensures that BGBTC's backing can be independently audited at any time without relying on manual disclosures. 'Chainlink Proof of Reserve, the industry standard, offers real-time monitoring, enabling users to independently verify asset collateralization, and bringing increased transparency and trust to onchain products. We are excited about Bitget's integration of Chainlink Proof of Reserve to back its BGBTC, establishing a robust framework that fuels the ongoing expansion of DeFi,' said Johann Eid, Chief Business Officer, Chainlink Labs. The adoption of Chainlink Proof of Reserve reinforces Bitget's commitment to setting a higher standard for transparency and trust in the digital asset industry. Complementing its existing Proof of Reserve and industry-leading Protection Fund, this integration ensures users can trade with greater confidence, knowing their assets are backed and verifiable in real time. Together, these measures cement Bitget's position as a security-first exchange, dedicated to safeguarding user interests in an evolving market landscape. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real-time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non-custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi-chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world's most thrilling championships. For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet For media inquiries, please contact: media@ About Chainlink Chainlink is the backbone of the blockchain industry, the global standard for connecting blockchains to real-world data, other blockchains, governments, and enterprise systems. Chainlink has enabled tens of trillions in transaction value across the blockchain economy, powering critical use cases across DeFi, banking, tokenized real-world assets (RWAs), cross-chain, and more. Chainlink is widely adopted by major financial market infrastructures, institutions, and top DeFi protocols, including Swift, Euroclear, Mastercard, Fidelity International, UBS, ANZ, Aave, GMX, Lido, and many more. Learn more by visiting Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use. A photo accompanying this announcement is available at
Toronto Star
32 minutes ago
- Toronto Star
SONORO GOLD ANNOUNCES $525,000 PRIVATE PLACEMENT
VANCOUVER, Canada, Aug. 20, 2025 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) ('Sonoro' or the 'Company') announces a non-brokered private placement offering (the 'Offering') consisting of 3,500,000 units (the 'Units') at a price of CAD $0.15 per Unit, for gross proceeds of CAD $525,000. Each Unit will be composed of one Sonoro common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional Sonoro common share for a period of two years from the closing of the private placement at an exercise price of CAD $0.22 per share.
